Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Anthony Shields, Barbara Ann Karmanos Cancer Institute Identifier:
First received: July 7, 2009
Last updated: March 29, 2017
Last verified: March 2017

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Condition Intervention
Brain and Central Nervous System Tumors
Chronic Myeloproliferative Disorders
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Unspecified Adult Solid Tumor, Protocol Specific
Device: 3'-deoxy-3'-[18F]fluorothymidine

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Intervention Model Description:
PET scans will be performed to show the distribution throughout the body of substances containing a small amount of radioactive material.
Masking: No masking
Primary Purpose: Diagnostic
Official Title: Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)

Resource links provided by NLM:

Further study details as provided by Barbara Ann Karmanos Cancer Institute:

Primary Outcome Measures:
  • Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs [ Time Frame: at time of PET or CT PET Scan ]
  • Changes in thymidine kinase, thymidylate synthase, and standardized uptake values [ Time Frame: before and after therapy ]

Secondary Outcome Measures:
  • FLT PET response rate [ Time Frame: up to 2 hours during PET scan ]

Estimated Enrollment: 80
Study Start Date: September 2009
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 3'-deoxy-3'-[18F]fluorothymidine
The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
Device: 3'-deoxy-3'-[18F]fluorothymidine
The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
Other Name: PET Scan

Detailed Description:



  • Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer.


  • Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment.

OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography imaging procedures.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Meets one of the following criteria:

    • Histologically confirmed solid tumor or hematologic malignancy
    • Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging


  • Able to lie still in the PET scanner
  • Girth and weight must be suitable to enter the gantry
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00935090

United States, Michigan
Barbara Ann Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201-1379
Contact: Clinical Trials Office - Barbara Ann Karmanos Cancer Institute    800-527-6266      
Sub-Investigator: Shirish Gadgeel, M. D.         
Sub-Investigator: Ulka Vaishampayan, M.D.         
Sub-Investigator: Antoinette Wozniak, M.D.         
Sub-Investigator: Patricia LoRusso, D.O.         
Sub-Investigator: Elisabeth Heath, M.D.         
Sub-Investigator: Muaiad Kittaneh, M.D.         
Sub-Investigator: Ajay Kumar, Ph.D.         
Sub-Investigator: Laurel E. Stroempl, PA         
Sub-Investigator: Otto Muzik, Ph.D.         
Sub-Investigator: Lance Heilbrun, Ph.D.         
Sub-Investigator: Thomas Mangner, Ph.D.         
Sub-Investigator: Anteneh Tesfaye, M.D.         
Sub-Investigator: Manish Thakur, M.S.         
Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Anthony F. Shields, MD, PhD Barbara Ann Karmanos Cancer Institute
  More Information

Responsible Party: Anthony Shields, Principal Investigator, Barbara Ann Karmanos Cancer Institute Identifier: NCT00935090     History of Changes
Other Study ID Numbers: CDR0000647210
P30CA022453 ( US NIH Grant/Contract Award Number )
WSU-2006-127 ( Other Identifier: Wayne State University - Human Investigation Committee )
Study First Received: July 7, 2009
Last Updated: March 29, 2017

Keywords provided by Barbara Ann Karmanos Cancer Institute:
essential thrombocythemia
unspecified adult solid tumor, protocol specific
accelerated phase chronic myelogenous leukemia
acute undifferentiated leukemia
adult acute lymphoblastic leukemia in remission
adult acute myeloid leukemia in remission
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
atypical chronic myeloid leukemia, BCR-ABL negative
blastic phase chronic myelogenous leukemia
chronic myelomonocytic leukemia
chronic phase chronic myelogenous leukemia
mast cell leukemia
meningeal chronic myelogenous leukemia
progressive hairy cell leukemia, initial treatment
prolymphocytic leukemia
recurrent adult acute lymphoblastic leukemia
recurrent adult acute myeloid leukemia
recurrent adult T-cell leukemia/lymphoma
refractory chronic lymphocytic leukemia
refractory hairy cell leukemia
relapsing chronic myelogenous leukemia
secondary acute myeloid leukemia
stage I adult T-cell leukemia/lymphoma
stage I chronic lymphocytic leukemia
stage II adult T-cell leukemia/lymphoma
stage II chronic lymphocytic leukemia

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Myelodysplastic Syndromes
Nervous System Neoplasms
Central Nervous System Neoplasms
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pathologic Processes
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Precancerous Conditions
Neoplasms by Site processed this record on May 24, 2017